ENSC
Ensysce Biosciences, Inc.
$0.28
-0.02 (-6.44%)
At close · Jul 7
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$4.04M
Shares
14,694,492
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.28
Open$0.29
Day$0.27–0.29
52W$0.23–2.75
Avg vol 30d1.0M
Short int364K · 2.5% float · 1.0d
Short vol48%
Last earningsMay 18, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−73%
below
Price vs 50-day avg
−10%
below
RSI (14)
45
neutral
MACD trend
Positive
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+9%
trailing
6-month return
−70%
trailing
YTD return
−70%
this year
Relative strength
−77%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 15 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.48% of float · ▲ +619.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — mid 1-yr range
Squeeze score
44
elevated · 0–100
Fundamentals
Revenue growth
−3%
Y/Y
EPS growth
+65%
Y/Y
Free cash flow
$-7.9M
Balance sheet
$4.3M
net cash
Quant / Vol
risk profile
Volatility
115%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
9.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 19, 2026
Est · unconfirmed
· in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−73%
Bearish
Price vs 50-day avg
−10%
Bearish
RSI (14)
45
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 15 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.48% of float · ▲ +619.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 2%
52-wk high $3
vs 200-day avg -73%
vs 50-day avg -10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENSC
this stock
Ensysce Biosciences, Inc.
|
$4.04M | -70.0% | -2.8% | — | 2.5% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENSC | -7.1% | +8.7% | -69.5% | -4.8% | -70.0% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -8.0% | +7.3% | -77.1% | -5.0% | -79.7% |